Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

Also called NCT05598333

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
AskBio Inc (from the registry)
Registry
  • NCT NCT05598333
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Netherlands, Poland, Romania, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05598333. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-20 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
Acronym
GenePHIT
Condition
Congestive Heart Failure
Intervention (Drug)
AB-1002
Lead sponsor
AskBio Inc (class: industry)

Record details

Record id
cardio:ct-nct05598333
Content hash
39652e33fd0a6577d84c6f4dadf756b3289b80dc6aa50cd3ee603bfe885f425c